Tempus AI (TEM) announced it has entered into a definitive agreement to acquire Personalis, Inc. (PSNL) for a total enterprise value of $1.5 billion. The acquisition is intended to integrate Personalis's minimal residual disease (MRD) technology into Tempus's AI-enabled precision oncology platform, expanding its capabilities across the cancer care continuum from diagnosis to long-term patient monitoring.
Key Details
- Transaction Value: Personalis shareholders will receive consideration of $16.25 per share, for a total enterprise value of $1.5 billion.
- Deal Structure: The transaction is structured as a 100% stock deal, with Tempus having the option to pay up to 50% of the consideration in cash.
- Strategic Rationale: The acquisition aims to combine Personalis's leadership in the rapidly growing, $20 billion MRD market with Tempus's commercial scale, multimodal data, and AI platform.
- Timeline: The deal, approved by both boards, is expected to close in late 2026 or early 2027, subject to Personalis shareholder and regulatory approvals.